(:CVRS)

Oct 25, 2019 08:45 am ET
Corindus Vascular Robotics, Inc. Stockholders Approve Acquisition by Siemens Healthineers
At a special meeting today, stockholders of Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS) approved the adoption of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 7, 2019, by and among Siemens Medical Solutions USA, Inc. (“SMS USA”), Corpus Merger Inc. (“Merger Sub”) and Corindus. Subject to the terms and conditions of the Merger Agreement, Merger Sub, a wholly owned subsidiary of SMS USA, will be merged with and into Corindus, with Corindus surviving the merger as a wholly owned subsidiary of SMS USA. The Company’s stockhold
Oct 08, 2019 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against Corindus Vascular Robotics, Inc.
Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Corindus Vascular Robotics, Inc. (“Corindus”) (NYSE...
Sep 18, 2019 06:45 am ET
Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascular Therapeutics 2019 Conference
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it will showcase the capabilities of the CorPath® GRX system at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference, to be held September 25-29 in San Francisco, Calif
Sep 03, 2019 06:45 am ET
First-in-Human Telerobotic Coronary Intervention Procedures Published in The Lancet Journal, EClinicalMedicine
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has published the results from the
Aug 13, 2019 05:50 pm ET
CORINDUS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Corindus Vascular Robotics - CVRS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Corindus Vascular Robotics (NYSE: CVRS) to Siemens Healthineers AG. Under the terms of the proposed transaction, shareholders of Corindus will receive only $4.28 in cash for each share of Corindus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Aug 09, 2019 08:00 pm ET
URGENT: Monteverde & Associates PC is Investigating the Following Transaction
NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: ...
Aug 09, 2019 10:00 am ET
GCI, CBM, VSI and CVRS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Gannett Co., Inc. (NYSE: GCI) regarding possible breaches of fiduciary duties and other violations of law related to Gannett’s agreement to merge with New Media Investment Group Inc....
Aug 08, 2019 08:30 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on Behalf of Corindus Shareholders and Encourages Corindus Investors to Contact the
NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on behalf of Corindus shareholders concerning the proposed merger with a subsidiary of Siemens Healthineers AG....
Aug 08, 2019 04:56 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Corindus Vascular Robotics, Inc.
NEW YORK, Aug. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Corindus Vascular Robotics, Inc. ("Corindus" or the "Company") (NYSE: CVRS) in connection with the proposed acquisition of the Company by a subsidiary of Siemens Healthineers AG ("Siemens Healthineers").  Under the terms of the agreement, Corindus shareholders will receive $4.28 per CVRS share....
Aug 08, 2019 11:53 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Corindus Vascular Robotics, Inc. to Siemens Healthineers AG is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE: CVRS) stock prior to August 8, 2019. You are hereby notified that...
Aug 08, 2019 10:07 am ET
Corindus Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Corindus Vascular Robotics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Corindus Vascular Robotics, Inc. (NYSE AMERICAN: CVRS) to Siemens Healthineers AG for $4.28 per share is fair to Corindus shareholders. On behalf of Corindus...
Aug 08, 2019 06:45 am ET
Corindus Reports Second Quarter 2019 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2019.
Aug 08, 2019 01:00 am ET
Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers
Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion.
Aug 05, 2019 04:31 pm ET
Corindus to Present at Canaccord Genuity 39th Annual Growth Conference on August 8, 2019
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will present at the Canaccord Genuity 39th Annual Growth Conference as follows:
Jul 25, 2019 06:45 am ET
Corindus to Report Second Quarter 2019 Financial Results on August 8, 2019
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release second quarter 2019 financial and business results on Thursday, August 8, 2019 before the open of the U.S. financial markets.
Jul 18, 2019 06:45 am ET
Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks,
Jul 17, 2019 06:45 am ET
Corindus Announces Regulatory Approval of CorPath GRX for Neurovascular Intervention in Australia and New Zealand
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received approval from the Australian Therapeutic Goods Administration to commercialize its CorPath® GRX System for neurovascular interventions in Australia and New Zealand. The CorPath GRX System is already approved for percutaneous coronary and peripheral vascular interventions in the region.
Jul 09, 2019 04:20 pm ET
Corindus Announces First Commercial Installation of CorPath® GRX System in South America
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that
Jul 01, 2019 06:45 am ET
Corindus Joins Russell 3000® Index
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1.
May 23, 2019 06:45 am ET
Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the
May 20, 2019 06:45 am ET
Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the an
May 17, 2019 06:45 am ET
Corindus to Present “Evolution of Robotics: Automation, Remote Applications, and Beyond” at SCAI 2019 Breakfast Symposium on May 21, 2019
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, will sponsor a breakfast symposium on May 21, 2019 titled, “Evolution of Robotics: Automation, Remote Applications, and Beyond,” during the Society for Cardiovascular Angiog
May 07, 2019 04:05 pm ET
Corindus Reports First Quarter 2019 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2019.
May 07, 2019 07:00 am ET
Corindus Equips the World’s First Fully Robotic Catheterization Laboratory
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Va
Apr 29, 2019 04:15 pm ET
Corindus to Report First Quarter 2019 Financial Results on May 7, 2019
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Apr 15, 2019 06:45 am ET
Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardio
Apr 09, 2019 08:30 am ET
Market Trends Toward New Normal in Corindus Vascular Robotics, Stifel Financial, GMS, Nice, Retail Value, and Installed Building Products — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Corindus Vascular Robotics, Inc. (NYSE:CVRS), Stifel Financial Corporation...
Mar 29, 2019 06:45 am ET
Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarte
Mar 12, 2019 04:05 pm ET
Corindus Reports Fourth Quarter and Full Year 2018 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2018.
Mar 12, 2019 08:41 am ET
Corindus Vascular Robotics Announces Additional Closing of Private Placement
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 shares of the Company’s common stock on the same terms and at the same price of $1.3796 per share as the initial closing through the exercise of such preemptive rights and the purchase
Mar 05, 2019 06:50 am ET
Corindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S. financial markets.
Mar 05, 2019 06:45 am ET
Corindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 39th Annual Cowen Health Care Conference as follows:
Feb 26, 2019 09:17 am ET
Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The net proceeds are expected to be
Feb 14, 2019 06:45 am ET
Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the
Dec 06, 2018 06:45 am ET
Corindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary Intervention
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announces that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, December 4 and 5, 2018, in India. This study represents the world’s first percutaneous coronary i
Nov 28, 2018 08:10 am ET
Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kadmon Holdings, Inc. (NYSE:KDMN), Overstock.com, Inc. (NASDAQ:OSTK),...
Nov 07, 2018 04:30 pm ET
Corindus to Present at Upcoming 2018 Healthcare Conferences
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that management will present at two investor conferences in November as follows:
Nov 06, 2018 04:05 pm ET
Corindus Reports Third Quarter 2018 Results
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its third quarter ended September 30, 2018.
Oct 30, 2018 04:30 pm ET
Corindus to Report Third Quarter Financial Results on November 6, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S. financial markets.
Oct 18, 2018 07:55 am ET
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Corindus Vascular Robotics, Inc....
Oct 01, 2018 06:45 am ET
Corindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. I
Sep 24, 2018 06:45 am ET
Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 Conference
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego
Sep 17, 2018 04:30 pm ET
Corindus to Present at Ladenburg Thalmann 2018 Healthcare Conference
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference as follows:
Sep 14, 2018 06:45 am ET
Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical devi
Aug 23, 2018 06:45 am ET
Corindus to Present at 13th Annual Wells Fargo Securities Healthcare Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference. Details for the presentation include:
Aug 07, 2018 04:05 pm ET
Corindus Reports Second Quarter 2018 Results
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2018.
Aug 06, 2018 06:45 am ET
Corindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention Symposium
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that the CorPath GRX System will be showcased for peripheral applications at the 2018 Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D., Interventional Cardiologist and AMP course d
Aug 03, 2018 06:45 am ET
Corindus to Present at Canaccord Genuity 38th Annual Growth Conference
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
Aug 03, 2018 06:45 am ET
Corindus to Report Second Quarter Financial Results on August 7, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2018 after the close of trading on Tuesday, August 7, 2018.
Jul 19, 2018 08:49 am ET
Corindus Announces Significant Progress in the Development of Remote Vascular Robotic Technology with the CorPath GRX® System
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Ryan Madder, M.D., an interventional cardiologist at Spectrum Health, has successfully completed a remote percutaneous coronary intervention (PCI) in a porcine model using the CorPath GRX System f
Jul 11, 2018 06:45 am ET
Corindus Names Aquilla S. Turk, D.O. as Chief Medical Officer, Neuroendovascular
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Aquilla "Quill" Turk, D.O. has joined the company as Chief Medical Officer, Neuroendovascular. Dr. Turk is a practicing physician at the Medical University of South Carolina where he serves as Dir
Jun 20, 2018 08:30 am ET
Investor Expectations to Drive Momentum within John Bean Technologies, Arlington Asset Investment, Vuzix, HFF, Blackbaud, and Corindus Vascular Robotics — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of John Bean Technologies Corporation (NYSE:JBT), Arlington Asset Investment...
Jun 19, 2018 06:45 am ET
Corindus Promotes Doug Teany to Chief Operating Officer
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has appointed Douglas Teany, currently the company’s Senior Vice President of R&D and Operations, to Chief Operating Officer, effective immediately.
Jun 08, 2018 09:00 am ET
Corindus Announces Pharmaceutical and Medical Device Agency (PMDA) Approval of CorPath GRX System in Japan
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received Pharmaceutical and Medical Device Agency (PMDA) Approval for commercialization of its CorPath® GRX System in Japan. Japan is one of the largest markets in the world for per
May 08, 2018 04:05 pm ET
Corindus Reports First Quarter 2018 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2018.
Apr 27, 2018 04:05 pm ET
Corindus to Report First Quarter Financial Results on May 8, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the first quarter of 2018 after the close of trading on Tuesday, May 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Apr 26, 2018 08:10 am ET
Market Trends Toward New Normal in FormFactor, Corindus Vascular Robotics, Syntel, IQVIA Holdings, Hannon Armstrong Sustainable Infrastructure Capital, and Ennis — Emerging Consolidated Expectations,
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FormFactor, Inc. (NASDAQ:FORM), Corindus Vascular Robotics,...
Apr 23, 2018 06:45 am ET
Corindus Presents "Optimizing Care with CorPath GRX: Hot Topics in Robotic Interventions" at SCAI 2018 Dinner Symposium on April 26
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (
Mar 16, 2018 09:15 am ET
Corindus Announces $25 Million Private Placement of Series A Convertible Preferred Shares and Warrants
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into definitive agreements to issue newly-designated Series A Convertible Preferred Stock to a select group of existing investors including Hudson Executive Capital and BioStar Ven
Mar 14, 2018 04:05 pm ET
Corindus Reports Fourth Quarter and Full Year 2017 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2017.
Mar 13, 2018 04:02 pm ET
Corindus to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the fourth quarter of 2017 after the close of trading on Wednesday, March 14, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Mar 13, 2018 07:00 am ET
James R. Tobin Joins Corindus Board of Directors
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that James (Jim) Tobin has been appointed to its Board of Directors, effective immediately.
Mar 12, 2018 04:30 pm ET
Corindus to Present at Cowen Health Care Conference
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Health Care Conference hosted by Cowen in Boston, MA.
Mar 05, 2018 06:45 am ET
Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.
Mar 01, 2018 08:10 am ET
Recent Analysis Shows Mobile Mini, Corindus Vascular Robotics, Payment Data, STAAR Surgical, Voyager Therapeutics, and Sunshine Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mobile Mini, Inc. (NASDAQ:MINI), Corindus Vascular...
Feb 22, 2018 06:45 am ET
Delray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using Corindus CorPath® GRX System Following FDA Clearance
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System. The procedure was performed by Joseph Ricotta, M.D., Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt College of Medicine, FAU. CorPath GRX is the first and only FDA-cleared medical device to bring
Feb 20, 2018 06:45 am ET
Corindus Receives FDA Clearance for CorPath® GRX System in Peripheral Vascular Interventions
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.
Jan 23, 2018 05:15 pm ET
Corindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural Training
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled "Complex Radial Interventions on Robotic and Manual Platforms" is designed to familiarize participants with the operations and capabilities of robotic-assisted percutaneous coronary interventions (PCI) using the CorPath GRX
Jan 23, 2018 05:00 pm ET
Corindus Announces Preliminary Fourth Quarter and Full Year 2017 Revenue
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported preliminary revenue results for the fourth quarter and year ended December 31, 2017.
Jan 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive La
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Athersys, Inc. (NASDAQ:ATHX), Repros Therapeutics Inc....
Jan 02, 2018 04:30 pm ET
Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment Capabilities
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI), may enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of this lifesaving procedure. The global shortage of PCI-capable operators is significant and co
Dec 14, 2017 06:45 am ET
Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System outside of the United States. The system was purchased by the Apex Heart Institute in Ahmedabad, India, a state of the art cardiology center. Corindus will partner with Apex Heart Institute to develop a Global Center of Excellence to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).
Dec 01, 2017 06:45 am ET
Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical
Nov 07, 2017 04:05 pm ET
Corindus Vascular Robotics Reports Third Quarter 2017 Results
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for the quarter ended September 30, 2017.
Nov 02, 2017 04:15 pm ET
Corindus to Present at Upcoming Investor Conferences
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced the Company will be participating in two upcoming investor conferences.
Oct 27, 2017 04:37 pm ET
Corindus to Feature CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2017 Conference
Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it will be participating in the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Conference to be held October 29 – November 2 in Denver, CO. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the conference, including in the exhibit hall, presentations, and during a breakfast symposium.
Oct 24, 2017 04:15 pm ET
Corindus Vascular Robotics to Report Third Quarter 2017 Financial Results on November 7, 2017
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, November 7, 2017. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Oct 23, 2017 06:45 am ET
Corindus Evaluates Incorporating HeartFlow Technology with CorPath GRX System
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support.